Shanghai Fosun bids for India's Gland Pharma

23 May 2016

Shanghai-based Fosun Pharma (HK: 02196) has announced an indicative offer to buy Gland Pharma, which is based in Hyderabad, India, competing against the US pharma firm Baxter (NYSE: BAX), the other potential buyer.

Fosun said in a statement to The Pharma Letter’s local correspondent Wang Fangqing that this possible purchase, which was initiated through its investment arm in Hong Kong, could help strengthen Fosun’s drug business, especially in terms of drug manufacturing. Also, the deal could help Fosun become “more “internationalized.”

Gland is a major injectables supplier in the global market, offering varieties including syringes, vials and dry powders for clients including the Indian company Dr Reddy’s Laboratories and the UK pharma Mylan. Gland is owned by its founders and the American investment company KKR.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK